Autolus Therapeutics Ltd (AUTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) has a cash flow conversion efficiency ratio of -0.378x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-67.32 Million) by net assets ($178.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check asset allocation strategy of Autolus Therapeutics Ltd to assess the company's strategic physical and investment asset allocation.
Autolus Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Autolus Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See what is Autolus Therapeutics Ltd's book value for net asset value and shareholders' equity analysis.
Autolus Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Autolus Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metrogas SA
BA:METR
|
0.029x |
|
LB Foster Company
NASDAQ:FSTR
|
-0.060x |
|
Lindex Group
HE:LINDEX
|
-0.015x |
|
Diplomat Holdings Ltd
TA:DIPL
|
0.049x |
|
Orion Engineered Carbons SA
NYSE:OEC
|
-0.045x |
|
HiVi Acoustics Technology Co Ltd
SHE:002888
|
0.013x |
|
Excelsior Medical Co Ltd
TW:4104
|
-0.022x |
|
INNOX Advanced Materials Co.Ltd
KQ:272290
|
0.015x |
Annual Cash Flow Conversion Efficiency for Autolus Therapeutics Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Autolus Therapeutics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $178.13 Million | $-283.57 Million | -1.592x | -229.79% |
| 2024-12-31 | $427.32 Million | $-206.27 Million | -0.483x | +63.04% |
| 2023-12-31 | $111.47 Million | $-145.59 Million | -1.306x | -247.32% |
| 2022-12-31 | $298.67 Million | $-112.31 Million | -0.376x | +0.04% |
| 2021-12-31 | $313.32 Million | $-117.86 Million | -0.376x | +32.91% |
| 2020-12-31 | $210.03 Million | $-117.76 Million | -0.561x | -40.79% |
| 2019-12-31 | $254.84 Million | $-101.48 Million | -0.398x | -216.06% |
| 2018-12-31 | $205.14 Million | $-25.85 Million | -0.126x | 0.00% |
| 2018-09-30 | $205.14 Million | $-25.85 Million | -0.126x | -9.83% |
| 2017-12-31 | $142.60 Million | $-16.36 Million | -0.115x | +64.25% |
| 2016-12-31 | $30.69 Million | $-9.85 Million | -0.321x | -99.85% |
| 2015-12-31 | $20.71 Million | $-3.33 Million | -0.161x | -- |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more